Cyanotech Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYAN research report →
Price Chart
About the company
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian Astaxanthin, a powerful dietary antioxidant acclaimed for promoting skin health and supporting eye, joint, and immune system functions; it is utilized as both a dietary supplement and an ingredient. Another significant product is Hawaiian Spirulina Pacifica, a highly nutritious dietary supplement formulated to enhance energy levels, bolster the immune system, provide cardiovascular benefits, and deliver a rich source of antioxidant carotenoids.
- CEO
- Matthew Keith Custer
- IPO
- 1991
- Employees
- 83
- HQ
- Kailua-Kona, HI, US
Get TickerSpark's AI analysis on CYAN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.33M
- P/E
- -50.00
- PEG
- -0.20
- P/S
- 0.12
- P/B
- 0.41
- EV/EBITDA
- 4.03
- Div Yield
- 0.00%
- Gross Margin
- 35.41%
- Op Margin
- 2.28%
- Net Margin
- -0.25%
- ROE
- -0.87%
- ROIC
- 3.21%
Latest fiscal year · YoY change
- Revenue
- $26.59M+9.8%
- Gross Profit
- $8.67M+26.1%
- Op Income
- $-574,000
- Net Income
- $-1,282,000+60.0%
- EPS
- $-0.18+60.0%
- OCF Growth
- +119.6%
- FCF Growth
- +106.4%
- 52W High
- $0.57
- 52W Low
- $0.23
- 50D MA
- $0.49
- 200D MA
- $0.43
- Beta
- 0.11
- RSI (14)
- 38
- Avg Volume
- 1.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cyanotech reported a softer third quarter as lower sales and higher manufacturing costs pushed losses wider, while management emphasized inventory reductions, cash conservation, and a renewed sales-and-marketing push.· February 9, 2024
- Q3 net sales fell 5% year over year to $5.582 million, with weakness tied to macro pressure and lower Spirulina bulk sales.
- Gross profit slipped to $1.649 million and gross margin was 29.5%, down from 29.9% a year ago.
- Operating loss widened to $848,000, and net loss increased to $1.020 million, or $0.16 per diluted share.
- Cash and working capital declined to $661,000 and $3.7 million, respectively, as the company drew down inventory to conserve cash.
- Management is leaning on premium U.S.-grown/Hawaii-origin positioning, new commercial hires, and stronger e-commerce and digital marketing to drive sales.
Net sales for the third quarter of fiscal 2024 were $5.582 million, down 5% from $5.891 million in the prior-year quarter. Gross profit was $1.649 million with gross margin of 29.5%, versus $1.764 million and 29.9% a year ago. Operating loss was $848,000, compared with $404,000 last year. Net loss was $1.020 million, or $0.16 per diluted share, versus a net loss of $598,000, or $0.10 per diluted share, in the prior-year quarter. Cash was $661,000 and working capital was $3.7 million, versus $974,000 and $5.4 million as of March 31, 2023. Management did not provide quantified next-quarter or full-year guidance on the call.
Matt Custer said the macro environment has pressured sales, especially bulk Spirulina, and that customers are trading down to lower-cost private label and international ingredients. He framed Cyanotech’s response around a revitalized sales and marketing effort, including a new Chief Commercial Officer, stronger sales staffing, and a sharper message around premium quality, sustainable sourcing, and Hawaii-grown products. His tone was defensive but constructive, emphasizing transparency, authenticity, and consumer education as key differentiators.
Felicia Ladin said Q3 net sales were $5.582 million, gross profit was $1.649 million at a 29.5% margin, operating loss was $848,000, and net loss was $1.020 million or $0.16 per share. She attributed the wider loss to lower sales and higher manufacturing costs from matching production volumes to demand, which is below historical levels. She also noted cash of $661,000 and working capital of $3.7 million, and management said inventories of bulk Spirulina and Astaxanthin were drawn down to conserve cash.
Management said inventory trends reflected a deliberate drawdown of bulk Spirulina and Astaxanthin inventories to align stock with demand and conserve cash. On sales initiatives, management highlighted consumer-facing storytelling, unedited farm and facility video, social media education, and new hires including a Head of Global Sales and Business Development and an e-commerce manager. The questions and answers centered on operational discipline and how the company plans to improve sales in a price-sensitive market.
The company still believes consumers are not pulling back from supplements, and management sees an opening in premium, transparent, U.S.-grown positioning versus price-focused competitors. New commercial hires and a stronger digital strategy could help Cyanotech communicate its differentiation more effectively and rebuild demand. Inventory reduction may improve cash discipline if sales stabilize.
The call reflected ongoing pressure from macro softness, trading down to private label, and intense price competition in bulk ingredients. Lower sales, higher manufacturing costs, and a small cash balance leave limited room for error. Management did not provide explicit financial guidance, so investors are left with execution risk around whether the new sales strategy can offset current demand weakness.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 65.6%
- Shares Outstanding
- 7.39M
- Float Shares
- 4.85M
of shares held by institutions
10 13F filers
Buy/sell ratio 0.56. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Institutional Trust Company, N.A. | 10.56K | 0 |
| Blackrock Fund Advisors | 812 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 12, 25 | Miyashiro Jennifer A.S. | other | 50,000 |
| Aug 21, 25 | Miyashiro Jennifer A.S. | other | 0 |
| Aug 28, 25 | MULDER DAVID M | other | 50,000 |
| Aug 28, 25 | Vied David L | other | 50,000 |
| Aug 28, 25 | DAVIS MICHAEL A / | other | 50,000 |
| Jul 29, 25 | Custer Matthew Keith | other | 2,075 |
| Jul 29, 25 | Custer Matthew Keith | other | 2,075 |
| Jul 29, 25 | Nordin Amy Beth | other | 1,502 |
| Jul 29, 25 | Nordin Amy Beth | other | 525 |
| Jul 29, 25 | Nordin Amy Beth | other | 1,502 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CYAN coverage
Recent articles, reports, and earnings notes.
No research on CYAN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYAN report →Contrasting Cyanotech (OTCMKTS:CYAN) & Charlie’s (OTCMKTS:CHUCD)
defenseworld.net · Apr 21
Cyanotech Corporation (CYAN) Q2 2026 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Nov 11
Cyanotech Reports Financial Results for the Second Quarter of Fiscal 2026
businesswire.com · Nov 10
Cyanotech Reports Financial Results for the First Quarter of Fiscal 2026
businesswire.com · Aug 6
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2025
businesswire.com · Jun 20
Spirulina Beverages Market and Consumer Behaviour Analysis, 2025-2030 - Prolgae Spirulina Supplies, Cyanotech Corporation, FUL Foods, Sol-Ti, and Raw Juicery Lead the Projected $61 Million Market
globenewswire.com · Jan 21
CYAN Stock Surges 6.58% on U.S. OTC Market Amid Sector Decline
gurufocus.com · Oct 2
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2024
businesswire.com · Jun 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.